Reports Summarize DNA Vaccines Findings from Wuhan Institute of Virology (Comparison of multiple DNA vaccines for protection against cytomegalovirus infection in BALB/c mice)
By a News Reporter-Staff News Editor at Vaccine Weekly -- Researchers detail new data in Biotechnology. According to news reporting from Hubei, People's Republic of China, by NewsRx journalists, research stated, "Human cytomegalovirus (HCMV) causes serious HCMV-related diseases in immunocompromised people. Vaccination is the most effective measure to control infection with the pathogen, yet no vaccine has been licensed till now."
The news correspondents obtained a quote from the research from the Wuhan Institute of Virology, "We performed a head-to-head comparison of the protective abilities of multiple DNA vaccines in murine model of murine cytomegalovirus (MCMV) infection. Five DNA vaccines were constructed. Four encoding MCMV proteins gp34 (m04), p65 (M84), DNA helicase (M105), and immediate-early 1 protein pp89 (IE-1), respectively, which were reported to induce CD8+ T cell responses, were compared with the one expressing gB (M55), the neutralizing antibody target antigen, for immune protection in BALB/c mice. Mice were immunized with these DNA vaccines 1 to 4 times via intramuscular injection followed by electroporation, and were subsequently infected with a lethal dose (3 x LD50) of highly virulent SG-MCMV. Specific antibodies and IFN-gamma secreting splenocytes were detected by immunoblotting and ELISPOT, respectively. Protective abilities in mice provided by the vaccines were evaluated by residual virus titers in organs, survival rate and weight loss. These DNA vaccines, especially m04, M84 and IE-1, could effectively reduce the virus loads in salivary glands and spleens of mice, but they couldn't completely clear the residual virus. Survival rates of 100% in mice after a lethal dose of MCMV infection could be reached by more than one dose of M84 vaccine or two doses of m04 or IE-1 vaccine. Immunization with M55 or M105 DNA at four doses offered mice only 62.5% survival rate after the lethal challenge. The study demonstrated that DNA vaccines could effectively afford mice protection against infection with a highly virulent MCMV and that the protection offered by induced CD8+ T cell immunity might be superior to that by gB-specific antibodies."
According to the news reporters, the research concluded: "These results are valuable references for development and application of HCMV vaccines."
For more information on this research see: Comparison of multiple DNA vaccines for protection against cytomegalovirus infection in BALB/c mice. Virology Journal, 2014;11():1-9. Virology Journal can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; Virology Journal - www.virologyj.com)
Our news journalists report that additional information may be obtained by contacting C.Y. Huang, Chinese Academy Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Hubei, People's Republic of China. Additional authors for this research include H.D. Wang, S.T. Wu, H.Y. Chang, L.L. Liu, B. Peng, F. Fang and Z. Chen (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Hubei, Virology, Viral DNA, DNA Viruses, DNA Research, DNA Vaccines, Viral Vaccines, Betaherpesvirinae, Synthetic Vaccines, Biological Products, DNA Virus Infections, Cytomegalovirus Vaccines, Herpesviridae Infections, People's Republic of China, Cytomegalovirus Infections
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC